<H1>Chapter DOI: 10.1007/978-1-60327-829-4_23<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>42</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>38</td></tr><tr><td>BibStructured Count</td><td width="10%">40</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>32</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_23</td><td>BibArticle</td><td>Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther 1950;64:559&#8211;75.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_23</td><td>BibArticle</td><td>Kaplan E, Fels, IG, Kotlowski BR, et al. Therapy of carcinoma of the prostate metastatic to bone with P<Superscript>32</Superscript> labeled condensed phosphate. J Nucl Med 1960;1:1&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_23</td><td>BibArticle</td><td>Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71&#8211;96.</td><td><a href=http://dx.doi.org/10.3322/CA.2007.0010>10.3322/CA.2007.0010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_23</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_23</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_23</td><td>BibArticle</td><td>Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232&#8211;41.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.03.0841>10.1200/JCO.2005.03.0841</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_23</td><td>BibArticle</td><td>Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458&#8211;68.</td><td><a href=http://dx.doi.org/10.1093/jnci/94.19.1458>10.1093/jnci/94.19.1458</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_23</td><td>BibArticle</td><td>Licciardone JC. The epidemiology and medical management of low back pain during ambulatory medical care visits in the United States. Osteopath Med Prim Care 2008;2:11.</td><td><a href=http://dx.doi.org/10.1186/1750-4732-2-11>10.1186/1750-4732-2-11</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_23</td><td>BibArticle</td><td>Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer &#8211; Genitourinary Group Study 30853. Cancer 1993;72(12 Suppl):3793&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19931215)72:12+&lt;3793::AID-CNCR2820721706&gt;3.0.CO;2-U>10.1002/1097-0142(19931215)72:12+&lt;3793::AID-CNCR2820721706&gt;3.0.CO;2-U</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_23</td><td>BibArticle</td><td>Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933&#8211;41.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.1997.00234.x>10.1046/j.1464-410X.1997.00234.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_23</td><td>BibArticle</td><td>Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005;5:543&#8211;55.</td><td><a href=http://dx.doi.org/10.1038/nrc1648>10.1038/nrc1648</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_23</td><td>BibArticle</td><td>Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232&#8211;7; erratum in: J Clin Oncol 2004;22:3434.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.06.100>10.1200/JCO.2003.06.100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_23</td><td>BibArticle</td><td>Beer TM, Tangen CM, Bland LB, et al. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. J Urol 2004;172:2213&#8211;7; erratum in: J Urol 2005;174:1156.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000147771.92104.83>10.1097/01.ju.0000147771.92104.83</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_23</td><td>BibArticle</td><td>Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977;266:653&#8211;5.</td><td><a href=http://dx.doi.org/10.1038/266653a0>10.1038/266653a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_23</td><td>BibArticle</td><td>Ben-Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 1995;16:452&#8211;6.</td><td><a href=http://dx.doi.org/10.1097/00006231-199506000-00006>10.1097/00006231-199506000-00006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_23</td><td>BibArticle</td><td>Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28:495&#8211;504.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_23</td><td>BibArticle</td><td>Vinjamuri S, Ray S. Phosphorus-32: The forgotten radiopharmaceutical? Nucl Med Commun 2008;29:95&#8211;7.</td><td><a href=http://dx.doi.org/10.1097/MNM.0b013e3282f1d4eb>10.1097/MNM.0b013e3282f1d4eb</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_23</td><td>BibArticle</td><td>Henriksen G, Breist&#248;l K, Bruland &#216;S, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_23</td><td>BibArticle</td><td>Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I Study of Samarium-153 Lexidronam (153Sm-EDTMP) with Docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009;27:2436&#8211;42.</td><td><a href=http://dx.doi.org/10.1200/JCO.2008.20.4164>10.1200/JCO.2008.20.4164</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_23</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Fizazi</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Beuzeboc</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lumbroso</span></span>, et al.</aug> <span style='background:#CCCCFF'>A prospective Phase II trial of consolidation Docetaxel and Samarium-153 in patients with bone metastases from castration resistant prostate cancer</span>. <span style='background:#CCFF99'>J Clin Oncol</span> <span style='background:#66FF66'>2009</span>;<span style='background:#FFCC66'>27</span>:<span style='background:#D279FF'>2429&#8211;35</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_23</td><td>BibArticle</td><td>Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet 2001;357:336&#8211;41; erratum in: Lancet 2001;357:1210.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)03639-4>10.1016/S0140-6736(00)03639-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_23</td><td>BibArticle</td><td>Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79&#8211;86.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_23</td><td>BibArticle</td><td>Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999;52:101&#8211;9; erratum in: Radiother Oncol 1999;53:167; Leer J [corrected to Leer JW]; van Mierlo T [corrected to van Mierlo I].</td><td><a href=http://dx.doi.org/10.1016/S0167-8140(99)00110-3>10.1016/S0167-8140(99)00110-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_23</td><td>BibArticle</td><td>Wu JS, Monk G, Clark T, et al. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol) 2006;18:539&#8211;44.</td><td><a href=http://dx.doi.org/10.1016/j.clon.2006.05.003>10.1016/j.clon.2006.05.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_23</td><td>BibArticle</td><td>Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation of Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519&#8211;26.</td><td><a href=http://dx.doi.org/10.1016/S0302-2838(03)00364-6>10.1016/S0302-2838(03)00364-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_23</td><td>BibArticle</td><td>Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/0167-8140(94)90411-1>10.1016/0167-8140(94)90411-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_23</td><td>BibArticle</td><td>Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805&#8211;13.</td><td><a href=http://dx.doi.org/10.1016/0360-3016(93)90309-J>10.1016/0360-3016(93)90309-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_23</td><td>BibArticle</td><td>Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/0277-5379(91)90257-E>10.1016/0277-5379(91)90257-E</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_23</td><td>BibArticle</td><td>Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14:349&#8211;51.</td><td><a href=http://dx.doi.org/10.1007/BF00254382>10.1007/BF00254382</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Year, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR30_23</td><td>BibArticle</td><td>Kasalick&#253; J, Krajsk&#225; V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/s002590050309>10.1007/s002590050309</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_23</td><td>BibArticle</td><td>Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210&#8211;4.</td><td><a href=http://dx.doi.org/10.1007/s002590050143>10.1007/s002590050143</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_23</td><td>BibArticle</td><td>Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574&#8211;81.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_23</td><td>BibArticle</td><td>Sartor O, Reid RH, Hoskin PJ, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2004.01.034>10.1016/j.urology.2004.01.034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_23</td><td>BibArticle</td><td>Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637&#8211;43.</td><td><a href=http://dx.doi.org/10.1002/cncr.22431>10.1002/cncr.22431</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_23</td><td>BibArticle</td><td>Higano CS, Quick DP, Bushnell D, Sartor O. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer 2008;6:40&#8211;5.</td><td><a href=http://dx.doi.org/10.3816/CGC.2008.n.007>10.3816/CGC.2008.n.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_23</td><td>BibArticle</td><td>Nilsson S, Larsen RH, Fossa SD, et al. First Clinical Experience with &#945; emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451&#8211;59.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2244>10.1158/1078-0432.CCR-04-2244</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_23</td><td>BibArticle</td><td>Nilsson S, Franz&#233;n L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587&#8211;94.</td><td><a href=http://dx.doi.org/10.1016/S1470-2045(07)70147-X>10.1016/S1470-2045(07)70147-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_23</td><td>BibArticle</td><td>Baczyk M, Czepczy&#324;ski R, Milecki P, et al. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28:245&#8211;50.</td><td><a href=http://dx.doi.org/10.1097/MNM.0b013e32805b72a0>10.1097/MNM.0b013e32805b72a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_23</td><td>BibArticle</td><td>Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 1999;40:256&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40_23</td><td>BibArticle</td><td>Liepe K, Korzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153 Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28:623&#8211;30.</td><td><a href=http://dx.doi.org/10.1097/MNM.0b013e32825a6adc>10.1097/MNM.0b013e32825a6adc</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_23</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Berenson</span> <span style='background:#DDDDDD'>A.</span></span></aug> <span style='background:#FFD9B3'>Market Forces Cited in Lymphoma Drugs&#8217; Disuse</span>. <span style='background:#FFFF49'>New York Times</span>, July 14, <span style='background:#66FF66'>2007</span> <span style='background:#FF3300'>(http://www.nytimes.com/2007/07/14/health/14lymphoma.html</span>, <span style='background:#FFFF0F'>referenced 1/5/09</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_23</td><td>BibArticle</td><td>Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005;23:7904&#8211;10.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.01.2310>10.1200/JCO.2005.01.2310</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>